Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma
- 1 July 2005
- journal article
- Published by American Society of Hematology in Blood
- Vol. 106 (1) , 353-355
- https://doi.org/10.1182/blood-2005-01-0033
Abstract
The t(4;14) translocation detected by fluorescence in situ hybridization (FISH) is an independent prognostic factor for an adverse outcome of multiple myeloma (MM). Because t(4;14) uniquely results in fibroblast growth factor receptor 3 (FGFR3) expression, decalcified, paraffin-embedded bone marrow biopsies were immunostained for FGFR3, and its expression was correlated with the t(4;14) status. FISH detected t(4;14) in 16 (19%) of 85 MM patient specimens, and immunocytochemistry detected aberrant FGFR3 expression in 13 (15%). Twelve (75%) t(4;14)-positive cases expressed FGFR3, and 12 (92%) FGFR3-positive cases harbored a t(4;14). FGFR3 expression and t(4;14) were strongly correlated (P < .001). FGFR3 expression by immunohistochemistry was associated with the immunoglobulin A (IgA) isotype (P < .001), a shorter progression-free survival (median, 11.5 versus 25.8 months; P < .001), and a shorter overall survival (median, 19.2 versus 46.3 months; P < .001).Keywords
This publication has 20 references indexed in Scilit:
- CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myelomaBlood, 2005
- A Global Expression-based Analysis of the Consequences of the t(4;14) Translocation in MyelomaClinical Cancer Research, 2004
- Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myelomaBlood, 2004
- Clinical and biologic implications of recurrent genomic aberrations in myelomaBlood, 2003
- A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains anIGH/MMSET fusion transcriptBlood, 2003
- In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expressionBlood, 2003
- Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapyBlood, 2002
- Chromosome translocations in multiple myelomaOncogene, 2001
- Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3Nature Genetics, 1997
- Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myelomaProceedings of the National Academy of Sciences, 1996